Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares of Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00. Following the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at $16,029,155.48. The trade was a 9.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ying Du also recently made the following trade(s):

• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Trading Up 7.2 %

ZLAB opened at $34.00 on Wednesday. The stock has a market capitalization of $3.72 billion, a P/E ratio of -12.27 and a beta of 1.02. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $36.60. The firm’s fifty day simple moving average is $27.77 and its 200 day simple moving average is $26.06.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. On average, equities research analysts predict that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Institutional Trading of Zai Lab

A number of hedge funds and other institutional investors have recently made changes to their positions in ZLAB. GF Fund Management CO. LTD. acquired a new position in Zai Lab during the fourth quarter worth $29,000. Pictet Asset Management Holding SA bought a new stake in Zai Lab during the 4th quarter worth about $31,000. Barclays PLC boosted its stake in shares of Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares during the last quarter. US Bancorp DE grew its holdings in shares of Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after acquiring an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new stake in shares of Zai Lab in the fourth quarter valued at about $210,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Bank of America reaffirmed a “neutral” rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research note on Monday. Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.